Avalo Therapeutics (NASDAQ:AVTX) Cut to "Sell" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Avalo Therapeutics to “sell” from “hold,” contrasting with 12 analysts rating the stock “buy” and one issuing a “sell” rating. The consensus rating remains “Moderate Buy,” with an average price target of $45.10.
• Avalo shares opened at $16.12, down 6.2%, while the company reported a quarterly loss of $0.83 per share—$0.25 worse than analysts’ estimates. Analysts expect a full-year loss of $2.69 per share.
• Insiders sold 13,314 shares worth about $239,140 over the past 90 days, including a sale by the CFO, while institutional investors own 87.06% of the company.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Saturday, Wall Street Zen reports.

AVTX has been the subject of a number of other reports. Bank of America assumed coverage on shares of Avalo Therapeutics in a research report on Friday, June 12th. They set a "buy" rating and a $35.00 price target for the company. BTIG Research restated a "buy" rating and issued a $58.00 price objective on shares of Avalo Therapeutics in a report on Tuesday, June 16th. Guggenheim set a $48.00 price objective on shares of Avalo Therapeutics and gave the stock a "buy" rating in a report on Friday, August 7th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Avalo Therapeutics in a research report on Friday, July 24th. Finally, Weiss Ratings upgraded shares of Avalo Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, August 11th. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $45.10.

Avalo Therapeutics Stock Down 6.2%

Shares of Avalo Therapeutics stock opened at $16.12 on Friday. The firm has a market cap of $864.52 million, a PE ratio of -3.69 and a beta of 0.78. Avalo Therapeutics has a 52 week low of $9.54 and a 52 week high of $24.27. The business's fifty day simple moving average is $19.07 and its 200-day simple moving average is $17.05.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.25). As a group, equities analysts expect that Avalo Therapeutics will post -2.69 earnings per share for the current year.

Insider Activity

In other Avalo Therapeutics news, insider Mittie Doyle sold 1,450 shares of Avalo Therapeutics stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $18.00, for a total value of $26,100.00. Following the completion of the transaction, the insider directly owned 51,776 shares of the company's stock, valued at $931,968. The trade was a 2.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Christopher Sullivan sold 10,185 shares of the business's stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $17.62, for a total transaction of $179,459.70. Following the sale, the chief financial officer owned 39,900 shares in the company, valued at $703,038. This trade represents a 20.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 13,314 shares of company stock valued at $239,140. 4.46% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC boosted its stake in shares of Avalo Therapeutics by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 110,460 shares of the company's stock valued at $552,000 after buying an additional 2,648 shares during the period. Glenmede Trust Co. NA increased its stake in shares of Avalo Therapeutics by 25.8% during the first quarter. Glenmede Trust Co. NA now owns 25,730 shares of the company's stock worth $384,000 after buying an additional 5,280 shares during the period. California State Teachers Retirement System purchased a new stake in shares of Avalo Therapeutics during the second quarter worth approximately $196,000. Dimensional Fund Advisors LP acquired a new stake in Avalo Therapeutics in the third quarter valued at approximately $143,000. Finally, Boothbay Fund Management LLC acquired a new stake in Avalo Therapeutics in the second quarter valued at approximately $56,000. Institutional investors and hedge funds own 87.06% of the company's stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.